Physician profile
Jennifer Ann Java
NPI 1053046912
$14,465.84
in general payments reported to CMS, 2019-2025
27 companies · $4,095 in 2025
The $4,095 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $887 · 2023: $4,927 · 2024: $4,556 · 2025: $4,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,566.85 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,349.51 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $2,004.18 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Teva Pharmaceuticals USA, INC. | $1,809.22 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,298.53 | 2022-2025 | Ingrezza |
| Alkermes, INC. | $1,006.87 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $960.67 | 2022-2025 | Caplyta |
| Lundbeck LLC | $688.76 | 2022-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $686.16 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $541.49 | 2023-2025 | Trintellix |
| Noven Therapeutics, LLC | $475.63 | 2022-2025 | Xelstrym |
| Almatica Pharma LLC | $424.00 | 2023-2025 | Loreev Xr, Sertraline Hcl, Citalopram |
| Axsome Therapeutics, INC. | $422.84 | 2023-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $301.32 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $297.05 | 2024-2025 | Cobenfy |
| Corium, LLC | $279.54 | 2023-2025 | Azstarys |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $253.51 | 2024 | |
| Sunovion Pharmaceuticals INC. | $184.11 | 2022 | |
| Indivior INC. | $182.25 | 2022-2025 | Perseris, Sublocade |
| Vanda Pharmaceuticals INC. | $64.04 | 2023-2025 | Fanapt, Hetlioz |
| Collegium Pharmaceutical, INC. | $58.85 | 2025 | Jornay Pm |
| Tris Pharma INC | $49.25 | 2024-2025 | Dyanavel Xr |
| Noven Pharmaceuticals, INC. | $38.73 | 2023-2024 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $32.75 | 2024-2025 | Qelbree |
| Neos Therapeutics, Lp | $19.92 | 2025 | Adzenys Xr-Odt |
| Biogen, INC. | $15.10 | 2024 | |
| Novo Nordisk INC | $13.76 | 2022 | |
| Brainsway USA INC | $7.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Java listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.